Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiouracil SCHEMBL9097033 | 0.77 | TP53 (0.54) | — | |
| SCHEMBL25418259 | 0.74 | ATAD2 (0.60) | ATAD2UBE2NKDM3BTDP1KMT2A | |
| SCHEMBL25450 | 0.74 | — | — | |
| SCHEMBL28216801 | 0.73 | ATAD2 (0.58) | ATAD2UBE2NKDM3BTDP1KMT2A | |
| Thiouracil SCHEMBL29948586 | 0.71 | — | — | |
| Thiouracil SCHEMBL191107 | 0.71 | — | — | |
| Thiouracil SCHEMBL7804099 | 0.70 | DAO (0.30) | — | |
| Pyrimidine SCHEMBL29014623 | 0.69 | ATAD2 (0.46) | ATAD2UBE2NKDM3BTDP1KMT2A | |
| Thymine SCHEMBL29232704 | 0.68 | ATAD2 (0.76) | ATAD2UBE2NKDM3BTDP1KMT2A | |
| Thiouracil SCHEMBL4958659 | 0.66 | TP53 (0.66) | ATAD2UBE2NKDM3BTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110025628-B | RNA-regulatory oligonucleotides with improved properties for the treatment of neuromuscular disorders | 维科医疗有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-10450567-B2 | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene | CURNA, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180305693-A1 | TREATMENT OF DOWN SYNDROME GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A DOWN SYNDROME GENE | CURNA, INC. | 2018-10-25 | — | — | US | disclosed |
| WO-2016149418-A1 | METHODS AND COMPOSITIONS FOR LABELING TARGETS AND HAPLOTYPE PHASING | CELLULAR RESEARCH, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20120295952-A1 | TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY | CURNA, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2008058291-A2 | MODULAR APTAMER-REGULATED RIBOZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1254169-B1 | METHODS RELATING TO MODULATION OF TH2 CELL SUBSET ACTIVITY BY MODULATION OF XBP-1 ACTIVITY | HARVARD COLLEGE (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060100131-A1 | Modulation of stem cell differentiation by modulation of caspase-3 activity | OTTAWA HEALTH RESEARCH INSTITUTE (CA) | 2006-05-11 | — | — | US | disclosed |